Biotage AB (Biotage) offers a range of services, including drug discovery and development, diagnostics, and analytical testing, as well as sustainable workflow solutions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Biotage’s R&D initiatives focus on developing innovative products by improving existing technology and adding new functionality. The company is actively working on fully integrated workflow solutions for peptides, automated solutions for plasmid purification, and on-demand synthesis services for oligonucleotides for therapeutic applications. The integration of Astrea R&D has expanded capabilities in pharmaceutical discovery and development of biological medicines and advanced therapies. It is also investing in automation, connectivity, and AI to drive more efficient workflows and ensure compliance with regulations. Biotage AB has six R&D centers along with 16 R&D facilities worldwide. As of December 2024, Biotage had 331 patent grants and 135 patent applications. During FY2024, the company received 21 new patent grants and 4 new patent applications were submitted.